Clinical Trial: The Effect of Bevacizumab on Corneal Neovascularization

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: The Effect of Bevacizumab on Corneal Neovascularization

Brief Summary: Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Detailed Summary:

To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization.

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.


Sponsor: Instituto de Olhos de Goiania

Current Primary Outcome: The Effect of Bevacizumab on Corneal Neovascularization [ Time Frame: Compare the results ]

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography


Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Instituto de Olhos de Goiania

Dates:
Date Received: November 22, 2008
Date Started: January 2006
Date Completion:
Last Updated: December 1, 2011
Last Verified: November 2011